Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 6Phase 2/3 1Phase 1 1

Status

Completed 18Unknown 10Terminated 10Recruiting 7Active not recruiting 6Not yet recruiting 3Withdrawn 2

Sponsor Class

INDUSTRY 4OTHER 1NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Urinary Bladder Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 3Carcinoma, Transitional Cell 3

Interventions

Carboplatin 106Cisplatin 97Paclitaxel 78pembrolizumab 69Gemcitabine 59Pemetrexed 49Cyclophosphamide 46Docetaxel 45Dexamethasone 45durvalumab 44Capecitabine 44Radiotherapy 40Nivolumab 37Lenalidomide 37Specimen Handling 36Doxorubicin 36Rituximab 34Oxaliplatin 34Bevacizumab 33Magnetic Resonance Spectroscopy 32Fluorouracil 32atezolizumab 29Etoposide 29Vincristine 26Radiation 26Leucovorin 26Letrozole 24Bortezomib 24Fulvestrant 23Prednisone 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Active not recruiting × Mitomycin × Clear all
NCT06211764 2026-06-05

SunRISe-5

Janssen Research & Development, LLC

Phase 3 Active not recruiting
272 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT03775265 2026-05-29

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
475 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT05243550 2026-05-11

ENVISION

UroGen Pharma Ltd.

Phase 3 Active not recruiting
240 enrolled 20 charts 1 FDA
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04241185 2026-05-01

MK-3475-992

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
520 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT06331299 2026-01-15

UTOPIA

UroGen Pharma Ltd.

Phase 3 Active not recruiting
99 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06462001 2024-06-17

BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer

Nottingham University Hospitals NHS Trust

Phase 3 Active not recruiting
500 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡